The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer
Metrics: PDF 1274 views | HTML 2164 views | ?
Ao Liu1,2, Anqin Han2, Hui Zhu2, Li Ma3, Yong Huang3, Minghuan Li2, Feng Jin2, Qiuan Yang4 and Jinming Yu2
1School of Medicine, Shandong University, Jinan, China
2Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
3Department of Nuclear Medicine, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
4Department of Radiation Oncology, Qilu Hospital Affiliated to Shandong University, Jinan, China
Jinming Yu, email: email@example.com
Qiuan Yang, email: firstname.lastname@example.org
Keywords: non-small cell lung cancer, [18F] FDG PET/CT, epidermal growth factor receptor, mutation
Received: December 06, 2016 Accepted: March 15, 2017 Published: April 04, 2017
Many noninvasive methods have been explored to determine the mutation status of the epidermal growth factor receptor (EGFR) gene, which is important for individualized treatment of non-small cell lung cancer (NSCLC). We evaluated whether metabolic tumor volume (MTV), a parameter measured by [18F] fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) might help predict EGFR mutation status in NSCLC. Overall, 87 patients who underwent EGFR genotyping and pretreatment PET/CT between January 2013 and September 2016 were reviewed. Clinicopathologic characteristics and metabolic parameters including MTV were evaluated. Univariate and multivariate analyses were used to assess the independent variables that predict mutation status to create prediction models. Forty-one patients (41/87) were identified as having EGFR mutations. The multivariate analysis showed that patients with lower MTV (MTV≤11.0 cm3, p=0.001) who were non-smokers (p=0.037) and had a peripheral tumor location (p=0.033) were more likely to have EGFR mutations. Prediction models using these criteria for EGFR mutation yielded a high AUC (0.805, 95% CI 0.712–0.899), which suggests that the analysis had good discrimination. In conclusion, NSCLC patients with EGFR mutations showed significantly lower MTV than patients with wild-type EGFR. Prediction models based on MTV and clinicopathologic characteristics could provide more information for the identification of EGFR mutations.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.